CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Certolizumab pegol

Last Updated: September 7, 2018
Result type: Reports
Project Number: SR0394
Product Line: Common Drug Review

Generic Name: Certolizumab pegol

Brand Name: Cimzia

Manufacturer: UCB Canada Inc.

Indications: Arthritis, psoriatic

Submission Type: New Indication

Project Status: Complete

Date Recommendation Issued: April 17, 2015

Recommendation Type: List with criteria/condition